Upgrade to remove ads
Only $35.99/year

12SA

Terms in this set (15)

Receipt of a live, attenuated vaccine for yellow fever:
2 week deferral; If a potential donor has received a live attenuated or bacterial vaccine such as measles, mumps, oral polio, typhoid, or yellow fever, there is a 2-week deferral; if the donor has received a live attenuated vaccine for rubella (German measles) or chickenpox, there is a 4-week deferral. Modern Blood Banking and Transfusion Practices, 7th Ed. Chapter 13.
For female prospective allogeneic blood donors, the minimum Hgb level is [ Select ] ["13.0 g/dL", "11.0 g/dL", "12.5 g/dL"] . For male prospective allogeneic blood donors, the minimum Hgb level is [ Select ] ["11.0 g/dL", "13.0 g/dL", "12.5 g/dL"] .
For autologous blood donors (male or female), the minimum Hgb level is [ Select ] ["12.5 g/dL", "13.0 g/dL", "11.0 g/dL"] .
12.5 g/dL; 13.0 g/dL; 11.0 g/dL
A prospective blood donor has been approved for blood donation; however, the donor weighs 102 lbs. What is the allowable limit of whole blood that can be drawn from this individual, and how much anticoagulant needs to be removed from the bag?
417 mL of whole blood can be drawn; remove 5 mL of anticoagulant; If a donor weighs less than 110 lb., you must remove anticoagulant from the bag. Each standard 450 mL whole blood bag has 63 mL of anticoagulant.

First calculate the amount of blood to be drawn:
Donor's weight (lb) x 450 mL / 110 lb = allowable amount to draw (mL)
(Allowable amount to draw / 100) x 14 = anticoagulant needed (mL)
Then, to calculate the amount of anticoagulant to remove:
63 mL - anticoagulant needed (mL) = amount of anticoagulant to remove (mL)
A prospective male allogeneic blood donor's information is as follows. Which of the following apply?
Age: 19 years old
Weight: 185 lb
Temperature: 37.4 degrees C
Pulse: 80
Blood Pressure: 110/65
Hgb: 13.6 g/dL
Acceptable for donation
A prospective blood donor has a history of a positive syphilis test, but was treated 4 months ago and has been asymptomatic since.
Defer from donation today; Prospective donors with a history of syphilis or gonorrhea or treatment for either, a reactive screening test for syphilis, or where no confirmatory test was performed, should be deferred for 12 months after completion of therapy. Modern Blood Banking and Transfusion Practices, 7th Ed. Chapter 13
If the donor received treatment 4 months ago, the donor should be deferred for an additional 8 months (12 months total).
The minimum count for plateletpheresis must be above [ Select ] ["150,000/ uL", "200,000/ uL", "250,000/ uL"] . The interval between plateletpheresis donations is at least [ Select ] ["3", "5", "4", "2"] days, not to exceed more than [ Select ] ["twice a week", "once a week"] , or more than [ Select ] ["24", "12", "52", "48"] times per year.
150,000/ uL; 2; twice a week; 24
A prospective female allogeneic blood donor has had a history of viral hepatitis. She was diagnosed at the age of 24.
Permanent deferral; If a donor has a clinical history or diagnosis of viral hepatitis at age 11 or later, then the donor must be permanently deferred. Modern Blood Banking and Transfusion Practices, 7th Ed. Chapter 13.
Which of the following infectious diseases is currently screened for on all blood donations?
Zika; Chikungunya, CMV, and Babesia are not universally screened for in all blood donations. Zika RNA has been found in asymptomatic blood donors. Since the end of 2016, all donor blood collected in the United States has been tested for Zika virus RNA using nucleic acid testing (NAT). Modern Blood Banking and Transfusion Practices, 7th Edition. Chapter 14, page 317.
Under the auspices of the FDA, blood is regarded both as a biologic and a [ Select ] ["drug", "treatment", "medical device"] . The regulations for donor screening are outlined in the [ Select ] ["CFR", "CMS", "CDC", "CBER"] , Title 21, parts 211, [ Select ] ["500-699", "850-999", "600-799"] .
drug; CFR; 600-799; The U.S. Food and Drug Administration (FDA) is a regulating agency. Its regulations for donor screening are outlined in the Code of Federal Regulations (CFR), Title 21, parts 211, 600-799. Under the auspices of the FDA, blood is regarded both as a biologic and a drug.
In 1988, the Center for Biologics Evaluation and Research (CBER) was formed. CBER is responsible for regulating the collection of blood and blood components used for transfusion and for the manufacture of pharmaceuticals derived from blood and blood components. CBER develops and enforces quality standards, inspects blood establishments, and monitors reports of errors, accidents, and adverse clinical events. Modern Blood Banking and Transfusion Practices, 7th Ed. Chapter 13, page 282.
Which of the following are the correct donor screening tests for hepatitis B?
HBsAg, anti-HBc, HBV DNA (NAT); Hepatitis B is a DNA (not an RNA) virus. The three required screening tests are:
HBsAg (testing for the hepatitis B surface antigen itself--not antibodies to it)
anti-HBc (antibodies to the hepatitis B core antigen).
HBV DNA by nucleic acid test (NAT)
Modern Blood Banking and Transfusion Practices, 7th Ed. Chapter 14, page 326, Table 14-5.
Which of the following are the correct screening tests for HIV?
anti-HIV antibodies (types 1 and 2), HIV-1 RNA (NAT); The current requires screening tests for HIV are as follows:
Anti-HIV antibodies (antibodies to types 1 and 2)
HIV-1 RNA nucleic acid test (NAT)
Modern Blood Banking and Transfusion Practices, 7th Ed. pages 313-314, page 326 Table 14-5.
Which of the following are the correct screening tests for hepatitis C?
anti-HCV antibodies, HCV RNA (NAT); Hepatitis C is an RNA virus. The current screening tests for hepatitis C are:
Anti-HCV antibodies by ELISA, ChLIA
HCV RNA by nucleic acid testing (NAT)
Modern Blood Banking and Transfusion Practices, 7th Ed. Chapter 14. Page 310, 326 Table 14-5.
Which of the following is a single-stranded RNA lipid-enveloped member of the Flavivirus family and is a human, avian, and equine neuropathogen?
West Nile virus (WNV); Like West Nile virus (WNV), the virus that causes hepatitis C (HCV) is an RNA virus and member of the Flavivirus family; however, HCV is not a human, avian, and equine neuropathogen.
CMV is a member of the herpesviruses.
Chikungunya virus is a member of the Togaviridae family of viruses.
Modern Blood Banking and Transfusion Practices, 7th Ed. Chapter 14.
For which of the following blood borne pathogens is a nucleic acid test (NAT) the only donor screening test?
WNV; There is currently only one screening test for West Nile virus: WNV RNA by nucleic acid testing (NAT).
Hepatitis C: anti-HCV antibodies and HCV RNA (NAT)
HIV: anti-HIV1/2 antibodies and HIV-1 RNA (NAT)
Hepatitis B: HBsAg, anti-HBc antibodies, HBV DNA (NAT)
Modern Blood Banking and Transfusion Practices, 7th Ed. Chapter 14.
Which of the following is a prion disease, for which there is no FDA-approved laboratory test?
Creutzfeldt-Jakob disease; Creutzfeldt-Jakob disease (CJD) is one of the transmissible spongiform encephalopathies (TSEs). The causative agent of all TSEs is believed to be a prion, which is described as a self-replicating protein. Currently, there is no reliable diagnostic test that can detect asymptomatic individuals. Therefore, deferral of donors with connection to the United Kingdom and parts of Europe as well as other associated risk factors is used to prevent transmission.
Modern Blood Banking and Transfusion Practices, 7th Ed. Chapter 14. Page 324
Students also viewed